{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:45:37Z","timestamp":1790109937532,"version":"4.0.1"},"reference-count":42,"publisher":"Bioscientifica","issue":"1","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,23]]},"abstract":"<jats:p>\n                    Cytotoxic T lymphocyte-associated protein 4 (CTLA4), a negative regulator typically expressed on the surface of T lymphocytes, is targeted by immunotherapy in patients with an ever-expanding spectrum of cancers. Characterizing the expression of CTLA4 in the pituitary gland could provide additional rationale for using immune checkpoint inhibitors in pituitary adenoma patients who do not respond to conventional treatments. We assessed the expression of CTLA4 mRNA and protein in a panel of 157 human pituitary glands, 45 collected at autopsy and 112 at surgery. These specimens included 50 normal glands and 107 adenomas: 41 nonsecreting, 25 PRL-, 24 ACTH-, 11 GH-, 2 TSH-, 1 FSH-secreting, and 3 atypical. Specimens were stained for CTLA4 and adenohypophyseal hormones using RNAscope\n                    <jats:italic>in situ<\/jats:italic>\n                    hybridization, immunohistochemistry, and RNAscope Multiplex Fluorescent Assay. CTLA4 mRNA was detectable in most normal pituitary glands (48 of 50, 96%) but varied in expression, with a histological score (H-score) ranging from 0.6 to 20. The variation did not depend upon the patient\u2019s gender and age and was not significantly affected by the archival storage time. CTLA4 expression was higher (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.022) in pituitary adenomas than normal glands, with the greatest levels seen in PRL- and GH-secreting adenomas (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.009 and 0.023 versus normal, respectively). Eight of 25 (32%) prolactinomas and 3 of 11 (27%) GH-adenomas had an H-score greater than 20, while no differences were seen for the other types. These novel data highlight the expression of an immune checkpoint such as CTLA4 on pituitary endocrine cells, a finding that could be exploited for therapeutical applications.\n                  <\/jats:p>","DOI":"10.1530\/erc-23-0196","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T12:01:57Z","timestamp":1698062517000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":3,"title":["\u0421ytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas"],"prefix":"10.1530","volume":"31","author":[{"given":"Elena","family":"Sabini","sequence":"first","affiliation":[{"name":"Department of Pathology, Johns Hopkins Hospital, School of Medicine, Baltimore, Maryland, USA"},{"name":"Department of Pathology, Johns Hopkins Hospital, School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins Hospital, School of Medicine, Baltimore, Maryland, USA"},{"name":"Department of Pathology, Johns Hopkins Hospital, School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6768-6308","authenticated-orcid":true,"given":"Patrizio","family":"Caturegli","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins Hospital, School of Medicine, Baltimore, Maryland, USA"},{"name":"Department of Pathology, Johns Hopkins Hospital, School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Journal of Immunology","first-page":"4762","article-title":"Regulation of surface and intracellular expression of CTLA4 on mouse T cells","volume":"157","author":"Alegre","year":"1996","unstructured":"Alegre MLNoel PJEisfelder BJChuang EClark MRReiner SL & Thompson CB1996Regulation of surface and intracellular expression of CTLA4 on mouse T cells. Journal of Immunology1574762\u20134770. (https:\/\/doi.org\/10.4049\/jimmunol.157.11.4762)"},{"key":"bib2","series-title":"Endocrine Pathology","first-page":"6","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","unstructured":"Asa SLMete OPerry A & Osamura RY2022Overview of the 2022 WHO classification of pituitary tumors. Endocrine Pathology336\u201326. (https:\/\/doi.org\/10.1007\/s12022-022-09703-7)"},{"key":"bib3","series-title":"American Journal of Clinical Pathology","first-page":"398","article-title":"Rapid loss of RNA detection by in situ hybridization in stored tissue blocks and preservation by cold storage of unstained slides","volume":"148","author":"Baena-Del Valle","year":"2017","unstructured":"Baena-Del Valle JAZheng QHicks JLFedor HTrock BJMorrissey CCorey ECornish TCSfanos KS & De Marzo AM2017Rapid loss of RNA detection by in situ hybridization in stored tissue blocks and preservation by cold storage of unstained slides. American Journal of Clinical Pathology148398\u2013415. (https:\/\/doi.org\/10.1093\/ajcp\/aqx094)"},{"key":"bib4","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1585","article-title":"Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment","volume":"108","author":"Burman","year":"2023","unstructured":"Burman PCasar-Borota OPerez-Rivas LG & Dekkers OM2023Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. Journal of Clinical Endocrinology and Metabolism1081585\u20131601. (https:\/\/doi.org\/10.1210\/clinem\/dgad098)"},{"key":"bib5","series-title":"American Journal of Pathology","first-page":"3225","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated Protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","unstructured":"Caturegli PDi Dalmazi GLombardi MGrosso FLarman HBLarman TTaverna GCosottini M & Lupi I2016Hypophysitis secondary to cytotoxic T-lymphocyte-associated Protein 4 blockade: insights into pathogenesis from an autopsy series. American Journal of Pathology1863225\u20133235. (https:\/\/doi.org\/10.1016\/j.ajpath.2016.08.020)"},{"key":"bib6","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"2729","article-title":"Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues","volume":"106","author":"Chen","year":"2009","unstructured":"Chen HLiakou CIKamat APettaway CWard JFTang DNSun JJungbluth AATroncoso PLogothetis C, 2009Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proceedings of the National Academy of Sciences of the United States of America1062729\u20132734. (https:\/\/doi.org\/10.1073\/pnas.0813175106)"},{"key":"bib7","series-title":"Neuroendocrinology","first-page":"333","article-title":"Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis","volume":"96","author":"Chen","year":"2012","unstructured":"Chen YWang CDSu ZPChen YXCai LZhuge QC & Wu ZB2012Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology96333\u2013342. (https:\/\/doi.org\/10.1159\/000339823)"},{"key":"bib8","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"632","article-title":"Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature","volume":"96","author":"Clayton","year":"2011","unstructured":"Clayton RNRaskauskiene DReulen RC & Jones PW2011Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. Journal of Clinical Endocrinology and Metabolism96632\u2013642. (https:\/\/doi.org\/10.1210\/jc.2010-1942)"},{"key":"bib9","series-title":"Endocrine Reviews","first-page":"431","article-title":"Molecular basis of combined pituitary hormone deficiencies","volume":"23","author":"Cohen","year":"2002","unstructured":"Cohen LE & Radovick S2002Molecular basis of combined pituitary hormone deficiencies. Endocrine Reviews23431\u2013442. (https:\/\/doi.org\/10.1210\/er.2001-0030)"},{"key":"bib10","series-title":"New England Journal of Medicine","first-page":"914","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","unstructured":"Colao APetersenn SNewell-Price JFindling JWGu FMaldonado MSchoenherr UMills DSalgado LRBiller BM, 2012A 12-month phase 3 study of pasireotide in Cushing's disease. New England Journal of Medicine366914\u2013924. (https:\/\/doi.org\/10.1056\/NEJMoa1105743)"},{"key":"bib11","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"61","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","unstructured":"Dekkers OMBiermasz NRPereira AMRomijn JA & Vandenbroucke JP2008Mortality in acromegaly: a metaanalysis. Journal of Clinical Endocrinology and Metabolism9361\u201367. (https:\/\/doi.org\/10.1210\/jc.2007-1191)"},{"key":"bib12","series-title":"Immunity","first-page":"23","article-title":"Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength","volume":"16","author":"Egen","year":"2002","unstructured":"Egen JG & Allison JP2002Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity1623\u201335. (https:\/\/doi.org\/10.1016\/s1074-7613(0100259-x)"},{"key":"bib13","series-title":"Pituitary","first-page":"283","article-title":"Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy","volume":"10","author":"Frohman","year":"2007","unstructured":"Frohman LA & Bonert V2007Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary10283\u2013289. (https:\/\/doi.org\/10.1007\/s11102-007-0042-x)"},{"key":"bib14","series-title":"Journal of Endocrinology","first-page":"R1","article-title":"LbetaT2 gonadotroph cells secrete follicle stimulating hormone (FSH) in response to active A","volume":"162","author":"Graham","year":"1999","unstructured":"Graham KENusser KD & Low MJ1999LbetaT2 gonadotroph cells secrete follicle stimulating hormone (FSH) in response to active A. Journal of Endocrinology162R1\u2013R5. (https:\/\/doi.org\/10.1677\/joe.0.162r001)"},{"key":"bib15","series-title":"Journal of Neuro-Oncology","first-page":"459","article-title":"Management of aggressive pituitary adenomas and pituitary carcinomas","volume":"117","author":"Heaney","year":"2014","unstructured":"Heaney A2014Management of aggressive pituitary adenomas and pituitary carcinomas. Journal of Neuro-Oncology117459\u2013468. (https:\/\/doi.org\/10.1007\/s11060-014-1413-6)"},{"key":"bib16","series-title":"New England Journal of Medicine","first-page":"2020","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","unstructured":"Hellmann MDPaz-Ares LBernabe Caro RZurawski BKim SWCarcereny Costa EPark KAlexandru ALupinacci Lde la Mora Jimenez E, 2019Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. New England Journal of Medicine3812020\u20132031. (https:\/\/doi.org\/10.1056\/NEJMoa1910231)"},{"key":"bib17","series-title":"New England Journal of Medicine","first-page":"711","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","unstructured":"Hodi FSO'Day SJMcDermott DFWeber RWSosman JAHaanen JBGonzalez RRobert CSchadendorf DHassel JC, 2010Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine363711\u2013723. (https:\/\/doi.org\/10.1056\/NEJMoa1003466)"},{"key":"bib18","series-title":"Nature","first-page":"417","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","unstructured":"Im SJHashimoto MGerner MYLee JKissick HTBurger MCShan QHale JSLee JNasti TH, 2016Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature537417\u2013421. (https:\/\/doi.org\/10.1038\/nature19330)"},{"key":"bib19","series-title":"Science Translational Medicine","first-page":"230ra45","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","unstructured":"Iwama SDe Remigis ACallahan MKSlovin SFWolchok JD & Caturegli P2014Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Science Translational Medicine6230ra45. (https:\/\/doi.org\/10.1126\/scitranslmed.3008002)"},{"key":"bib20","series-title":"Current Opinion in Rheumatology","first-page":"467","article-title":"Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus","volume":"29","author":"Izmirly","year":"2017","unstructured":"Izmirly PSaxena A & Buyon JP2017Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. Current Opinion in Rheumatology29467\u2013472. (https:\/\/doi.org\/10.1097\/BOR.0000000000000414)"},{"key":"bib21","series-title":"Molecular Human Reproduction","first-page":"84","article-title":"The CTLA-4 gene is expressed in placental fibroblasts","volume":"5","author":"Kaufman","year":"1999","unstructured":"Kaufman KABowen JATsai AFBluestone JAHunt JS & Ober C1999The CTLA-4 gene is expressed in placental fibroblasts. Molecular Human Reproduction584\u201387. (https:\/\/doi.org\/10.1093\/molehr\/5.1.84)"},{"key":"bib22","series-title":"Clinical Cancer Research","first-page":"1141","article-title":"Targeting PD-L1 initiates effective antitumor immunity in a murine model of Cushing disease","volume":"26","author":"Kemeny","year":"2020","unstructured":"Kemeny HRElsamadicy AAFarber SHChampion CDLorrey SJChongsathidkiet PWoroniecka KICui XShen SHRhodin KE, 2020Targeting PD-L1 initiates effective antitumor immunity in a murine model of Cushing disease. Clinical Cancer Research261141\u20131151. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3486)"},{"key":"bib23","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3925","article-title":"Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab","volume":"103","author":"Lin","year":"2018","unstructured":"Lin ALJonsson PTabar VYang TJCuaron JBeal KCohen MPostow MRosenblum MShia J, 2018Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. Journal of Clinical Endocrinology and Metabolism1033925\u20133930. (https:\/\/doi.org\/10.1210\/jc.2018-01347)"},{"key":"bib24","series-title":"Biochimica et Biophysica Acta","first-page":"60","article-title":"The 3' UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency","volume":"1779","author":"Malquori","year":"2008","unstructured":"Malquori LCarsetti L & Ruberti G2008The 3' UTR of the human CTLA4 mRNA can regulate mRNA stability and translational efficiency. Biochimica et Biophysica Acta177960\u201365. (https:\/\/doi.org\/10.1016\/j.bbagrm.2007.10.004)"},{"key":"bib25","series-title":"Journal of Clinical Investigation","first-page":"1370","article-title":"LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase","volume":"88","author":"Manns","year":"1991","unstructured":"Manns MPGriffin KJSullivan KF & Johnson EF1991LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. Journal of Clinical Investigation881370\u20131378. (https:\/\/doi.org\/10.1172\/JCI115443)"},{"key":"bib26","series-title":"Oncotarget","first-page":"76565","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","unstructured":"Mei YBi WLGreenwald NFDu ZAgar NYKaiser UBWoodmansee WWReardon DAFreeman GJFecci PE, 2016Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget776565\u201376576. (https:\/\/doi.org\/10.18632\/oncotarget.12088)"},{"key":"bib27","series-title":"Recent Progress in Hormone Research","first-page":"69","article-title":"Immortalization of neuroendocrine cells by targeted oncogenesis","volume":"47","author":"Mellon","year":"1991","unstructured":"Mellon PLWindle JJ & Weiner RI1991Immortalization of neuroendocrine cells by targeted oncogenesis. Recent Progress in Hormone Research4769\u201393. (https:\/\/doi.org\/10.1016\/b978-0-12-571147-0.50007-x)"},{"key":"bib28","series-title":"New England Journal of Medicine","first-page":"1277","article-title":"Nivolumab plus ipilimumab versus sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","unstructured":"Motzer RJTannir NMMcDermott DFAr\u00e9n Frontera OMelichar BChoueiri TKPlimack ERBarth\u00e9l\u00e9my PPorta CGeorge S, 2018Nivolumab plus ipilimumab versus sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine3781277\u20131290. (https:\/\/doi.org\/10.1056\/NEJMoa1712126)"},{"issue":"Supplement 4","key":"bib29","series-title":"Neuro-Oncology","first-page":"iv1","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011","volume":"16","author":"Ostrom","year":"2014","unstructured":"Ostrom QTGittleman HLiao PRouse CChen YDowling JWolinsky YKruchko C & Barnholtz-Sloan J2014CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011. Neuro-Oncology16(Supplement 4) iv1\u2013i63. (https:\/\/doi.org\/10.1093\/neuonc\/nou223)"},{"key":"bib30","series-title":"Immunology and Allergy Clinics of North America","first-page":"285","article-title":"Hypersensitivity reactions and immune-related adverse events to immune checkpoint inhibitors: approaches, mechanisms, and models","volume":"42","author":"Park","year":"2022","unstructured":"Park BCStone CAJrDewan AK & Johnson DB2022Hypersensitivity reactions and immune-related adverse events to immune checkpoint inhibitors: approaches, mechanisms, and models. Immunology and Allergy Clinics of North America42285\u2013305. (https:\/\/doi.org\/10.1016\/j.iac.2021.12.006)"},{"key":"bib31","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"E4223","article-title":"Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab","volume":"114","author":"Ramagopal","year":"2017","unstructured":"Ramagopal UALiu WGarrett-Thomson SCBonanno JBYan QSrinivasan MWong SCBell AMankikar SRangan VS, 2017Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proceedings of the National Academy of Sciences of the United States of America114E4223\u2013E4232. (https:\/\/doi.org\/10.1073\/pnas.1617941114)"},{"key":"bib32","series-title":"Clinical Cancer Research","first-page":"2424","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","unstructured":"Robert LTsoi JWang XEmerson RHomet BChodon TMok SHuang RRCochran AJComin-Anduix B, 2014CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clinical Cancer Research202424\u20132432. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2648)"},{"key":"bib33","series-title":"Journal of Clinical Medicine","article-title":"Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors","volume":"8","author":"Sato","year":"2019","unstructured":"Sato MTamura RTamura HMase TKosugi KMorimoto YYoshida K & Toda M2019Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors. Journal of Clinical Medicine8. (https:\/\/doi.org\/10.3390\/jcm8050695)"},{"key":"bib34","series-title":"Journal of Neurosurgery","first-page":"303","article-title":"Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes","volume":"114","author":"Sheehan","year":"2011","unstructured":"Sheehan JPPouratian NSteiner LLaws ER & Vance ML2011Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. Journal of Neurosurgery114303\u2013309. (https:\/\/doi.org\/10.3171\/2010.5.JNS091635)"},{"key":"bib35","series-title":"Endocrinology","first-page":"342","article-title":"Establishment of clonal strains of rat pituitary tumor cells that secrete growth hormone","volume":"82","author":"Tashjian","year":"1968","unstructured":"Tashjian AHJrYasumura YLevine LSato GH & Parker ML1968Establishment of clonal strains of rat pituitary tumor cells that secrete growth hormone. Endocrinology82342\u2013352. (https:\/\/doi.org\/10.1210\/endo-82-2-342)"},{"key":"bib36","series-title":"Molecular Endocrinology","first-page":"439","article-title":"Steroid and pulsatile gonadotropin-releasing hormone (GnRH) regulation of luteinizing hormone and GnRH receptor in a novel gonadotrope cell line","volume":"10","author":"Turgeon","year":"1996","unstructured":"Turgeon JLKimura YWaring DW & Mellon PL1996Steroid and pulsatile gonadotropin-releasing hormone (GnRH) regulation of luteinizing hormone and GnRH receptor in a novel gonadotrope cell line. Molecular Endocrinology10439\u2013450. (https:\/\/doi.org\/10.1210\/mend.10.4.8721988)"},{"key":"bib37","series-title":"Nature","first-page":"506","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","unstructured":"Ueda HHowson JMEsposito LHeward JSnook HChamberlain GRainbow DBHunter KMSmith ANDi Genova G, 2003Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature423506\u2013511. (https:\/\/doi.org\/10.1038\/nature01621)"},{"key":"bib38","series-title":"Trends in Immunology","first-page":"272","article-title":"CTLA-4 trafficking and surface expression","volume":"29","author":"Valk","year":"2008","unstructured":"Valk ERudd CE & Schneider H2008CTLA-4 trafficking and surface expression. Trends in Immunology29272\u2013279. (https:\/\/doi.org\/10.1016\/j.it.2008.02.011)"},{"key":"bib39","series-title":"European Journal of Endocrinology","first-page":"651","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","unstructured":"Vroonen LJaffrain-Rea MLPetrossians PTamagno GChanson PVilar LBorson-Chazot FNaves LABrue TGatta B, 2012Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology167651\u2013662. (https:\/\/doi.org\/10.1530\/EJE-12-0236)"},{"key":"bib40","series-title":"New England Journal of Medicine","first-page":"491","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","unstructured":"Wakelee HLiberman MKato TTsuboi MLee SHGao SChen KNDooms CMajem MEigendorff E, 2023Perioperative pembrolizumab for early-stage non-small-cell lung cancer. New England Journal of Medicine389491\u2013503. (https:\/\/doi.org\/10.1056\/NEJMoa2302983)"},{"key":"bib41","series-title":"Cancer Discovery","first-page":"1069","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","unstructured":"Wei SCDuffy CR & Allison JP2018Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery81069\u20131086. (https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367)"},{"key":"bib42","series-title":"Endocrinology","first-page":"4476","article-title":"The thyrotropin beta-subunit gene is repressed by thyroid hormone in a novel thyrotrope cell line, mouse T alphaT1 cells","volume":"139","author":"Yusta","year":"1998","unstructured":"Yusta BAlarid ETGordon DFRidgway EC & Mellon PL1998The thyrotropin beta-subunit gene is repressed by thyroid hormone in a novel thyrotrope cell line, mouse T alphaT1 cells. Endocrinology1394476\u20134482. (https:\/\/doi.org\/10.1210\/endo.139.11.6283)"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/31\/1\/ERC-23-0196.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/31\/1\/ERC-23-0196.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/31\/1\/ERC-23-0196.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:56:40Z","timestamp":1784555800000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/25779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":42,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/erc-23-0196","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]}}}